Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Sistemsko zdravljenje napredovalega diferenciranega raka ščitnice
Authors:Grašič-Kuhar, Cvetka (Author)
Language:Slovenian
Tipology:1.02 - Review Article
Organisation:Logo OI - Institute of Oncology
Abstract:Diferencirani rak ščitnice predstavlja preko 90 odstotkov raka ščitnice. Nastane iz folikularnih celic ščitnice in spada med visoko ozdravljive rake. Primarno zdravljenje je kirurško, visoko rizični za ponovitev prejmejo še adjuvantno radiojodno terapijo in tiroksin v supresijskem odmerku. Pri 7-23% bolnikov pride do pojava zasevkov v oddaljenih organih (pljuča, skelet). Temelj zdravljenja metastatskega diferenciranega raka ščitnice je radiojodna terapija. Pri pojavu rezistence na radiojodno terapijo je ob napredovanju bolezni sedaj na voljo zdravljenje s tarčnim zdravilom sorafenibom.
Keywords:rak ščitnice, napredovali rak, zdravljenje, preživetje
Year of publishing:2014
COBISS_ID:1963131 Link is opened in a new window
UDC:616.4-006
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-7YT5VXTU
Views:1509
Downloads:331
Files:.pdf PDF - Presentation file, download (508,96 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Systemic treatment of advanced differentiated thyroid cancer
Abstract:Differentiated thyroid cancer represents over 90 percents of thyroid cancers. It arises from thyroid follicular cells and is one of highly treatable cancers. Primary treatment is surgical and patients at high risk of carcinoma recurrence also receive adjuvant radioiodine therapy and a suppressive dose of thyroxin. In 7–23% of patients metastases appear in remote organs (lungs, skeleton). The basic treatment for metastatic differentiated thyroid cancer is radioiodine therapy. In case of resistance to radioiodine therapy during disease progression, treatment is now also possible with target medication sorafenib.

Archive

niGradiv

Back